Red Arrow Therapeutics, Inc. is a biotechnology company focusing on developing new technologies that can turn "cold" tumors into inflamed "hot" tumors. Red Arrow Therapeutics' lead product candidate, RA-001, a pH-activated polymer micelle loaded with IL-12, is designed to release fully active IL-12 upon sensing intratumoral pH to safely potentiate immunotherapy.
In the current pre-clinical data, RA-001 exhibits strong anti-tumor immunity in various tumor models. Furthermore, RA-001 shows high efficacy as monotherapy and in combination with immune checkpoint inhibitors.
Company Details
- Employees
- 8
- Founded
- 2021
- Address
- 1 Broadway, Cambridge,massachusetts 02142,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- https://redarrowtx.com
- HQ
- Cambridge, Massachusetts
Red Arrow Therapeutics Questions
Red Arrow Therapeutics's website is https://redarrowtx.com
Red Arrow Therapeutics's LinkedIn profile is https://www.linkedin.com/company/red-arrow-tx
Red Arrow Therapeutics has
8 employees.
View email and phone details for 8
employees at Red Arrow Therapeutics.
Red Arrow Therapeutics's industry is
Biotechnology Research
Red Arrow Therapeutics's top competitors are
Richi Lifesciences,
Takeda,
Metcela Inc.,
An Venture Partners,
Iteos Therapeutics,
Astellas Pharma,
Eli Lilly And Company,
Flagship Pioneering,
Peptidream Inc.,
Utec - The University Of Tokyo Edge Capital Partners.
Red Arrow Therapeutics's categories are Biotechnology Research
Red Arrow Therapeutics's founding year is 2021
